15.0007 - Phase 3 Randomized, Double-blind, Placebo Controlled, Multicenter Study to Compare the Efficacy & Safety of Lenalidomide Plus R-CHOP Chemotherapy (R2-CHOP) versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-Cell (ABC) Type Diffuse Large B-Cell Lymphoma (DLBCL). (The “ROBUST” Study)
To evaluate the effectiveness & safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (placebo-R-CHOP) chemotherapy in people who have previously untreated ABC type DLBCL